Ribo’s Divesiran (SLN124) Significantly Reduces Phlebotomy Frequency and Improves Patient QoL in Polycythemia Vera Phase IIa Trial

MPN Research Foundation Global

Overview

Divesiran (SLN124) from Ribo is an siRNA therapy designed to increase hepcidin levels, aiming to control erythrocyte overproduction in polycythemia vera (PV). Clinical trial results showed that patients treated with divesiran experienced a significant reduction in the frequency of phlebotomy procedures required during the study period compared to pre-treatment, alongside improved hematocrit control. Furthermore, follow-up data suggested a sustained delay in the need for phlebotomy even after the final dose, indicating substantial potential for enhancing patient quality of life.

In Depth

Key Findings

Clinical trials for Ribo’s siRNA therapeutic, Divesiran (SLN124), have demonstrated its effectiveness in controlling the overproduction of red blood cells in patients with polycythemia vera (PV), significantly reducing the frequency of phlebotomy. Divesiran modulates iron metabolism by increasing hepcidin levels, thereby suppressing erythrocyte production in the bone marrow. This clinical outcome is heralded as a groundbreaking advancement with the potential to substantially improve the quality of life (QoL) for PV patients.

Technical/Clinical Details

Divesiran (SLN124) utilizes small interfering RNA (siRNA) technology, specifically targeting an mRNA responsible for promoting hepcidin production in the body. Hepcidin is a master hormone regulating iron absorption and utilization; by elevating its levels, Divesiran effectively suppresses red blood cell production in the bone marrow. In PV patients, mutations such as JAK2 lead to excessive red blood cell production, increasing blood viscosity and the risk of thrombosis. Current treatments include phlebotomy, hydroxyurea, and interferon, each with their own limitations and side effects.

• Significant Reduction in Phlebotomy Frequency: The clinical trial demonstrated a statistically significant reduction in the number of phlebotomy procedures required during the study period for patients treated with Divesiran, compared to their pre-treatment baseline. This offers a major advantage by alleviating patients’ physical burden and reducing hospital visits.
• Improved Hematocrit Control: Alongside the reduced phlebotomy frequency, patients exhibited well-controlled hematocrit levels (the proportion of red blood cells in the blood). This is a critical indicator for managing thrombosis risk.
• Sustained Effect: Follow-up data suggests a persistent delay in the need for phlebotomy even after the final dose of Divesiran, indicating potential for a long-acting therapeutic effect.

These data strongly support Divesiran’s potential as an effective and patient-friendly new treatment option for managing polycythemia vera.

Background & Context

Polycythemia vera is a type of myeloproliferative neoplasm (MPN) characterized by the abnormal proliferation of red blood cells. If left untreated, it carries a high risk of thrombotic events like stroke and myocardial infarction, severely impairing QoL. The primary goal of current treatments is to maintain hematocrit levels within a normal range and reduce the risk of thrombotic events. However, existing therapies may offer insufficient QoL improvement or raise concerns regarding long-term safety. Targeted siRNA therapies like Divesiran are garnering significant anticipation from the medical community as a novel approach that can more specifically and efficiently control the disease pathology while reducing patient burden.

Strategic Significance & Outlook

The clinical trial results for Divesiran signify a major advance in PV treatment. This success suggests that siRNA technology can be a powerful tool for the long-term management of chronic diseases. Divesiran will now proceed through further large-scale clinical trials to establish its efficacy and safety, aiming for regulatory approval. If approved, Divesiran could dramatically improve the QoL for PV patients and become a new standard of care, slowing disease progression. This offers significant hope to the MPN patient community and could stimulate further development of hepcidin-targeting therapeutic strategies globally.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime